Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults

Benefits, risks, or burden?

Jean B. Nachega, Bernd Rosenkranz, Paul Pham

Research output: Contribution to journalArticle

Abstract

The recent development of once-daily antiretroviral agents and fixed-dose combination formulations has been an important development in antiretroviral regimen simplification. Recent studies indicate that once-daily antiretroviral regimens improve adherence, especially in antiretroviral-naïve patients and in difficult-to-treat populations, such as the homeless or marginally housed. However, there are potential risks with the higher peak and lower trough plasma drug concentrations that may result from certain once-daily formulations. Due to the multifactorial and complex nature of adherence behavior, clinicians' efforts to improve patient adherence should not be limited to prescribing once-daily regimens, but should also consider social support, side effect management, and adherence support tools, such as pillbox organizers and other targeted interventions. Additional research will clarify the benefits of once-daily and fixed-dose combination regimens on clinical and virologic outcomes. Comprehensive cost-benefit analysis of regimen simplification could help facilitate evidence-based decisions regarding antiretroviral regimen choices.

Original languageEnglish (US)
Pages (from-to)645-651
Number of pages7
JournalPatient Preference and Adherence
Volume5
DOIs
StatePublished - 2011

Fingerprint

Anti-Retroviral Agents
Patient Compliance
Social Support
Cost-Benefit Analysis
HIV
cost-benefit analysis
Research
Pharmaceutical Preparations
Population
social support
drug
Therapeutics
management
evidence

Keywords

  • Fixed-dose combination
  • Health care costs
  • Once-daily antiretroviral drugs
  • Regimen adherence
  • Regimen simplification

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Medicine (miscellaneous)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults : Benefits, risks, or burden? / Nachega, Jean B.; Rosenkranz, Bernd; Pham, Paul.

In: Patient Preference and Adherence, Vol. 5, 2011, p. 645-651.

Research output: Contribution to journalArticle

@article{d4aed498ce854db393f6c86f29273377,
title = "Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: Benefits, risks, or burden?",
abstract = "The recent development of once-daily antiretroviral agents and fixed-dose combination formulations has been an important development in antiretroviral regimen simplification. Recent studies indicate that once-daily antiretroviral regimens improve adherence, especially in antiretroviral-na{\"i}ve patients and in difficult-to-treat populations, such as the homeless or marginally housed. However, there are potential risks with the higher peak and lower trough plasma drug concentrations that may result from certain once-daily formulations. Due to the multifactorial and complex nature of adherence behavior, clinicians' efforts to improve patient adherence should not be limited to prescribing once-daily regimens, but should also consider social support, side effect management, and adherence support tools, such as pillbox organizers and other targeted interventions. Additional research will clarify the benefits of once-daily and fixed-dose combination regimens on clinical and virologic outcomes. Comprehensive cost-benefit analysis of regimen simplification could help facilitate evidence-based decisions regarding antiretroviral regimen choices.",
keywords = "Fixed-dose combination, Health care costs, Once-daily antiretroviral drugs, Regimen adherence, Regimen simplification",
author = "Nachega, {Jean B.} and Bernd Rosenkranz and Paul Pham",
year = "2011",
doi = "10.2147/PPA.S27558",
language = "English (US)",
volume = "5",
pages = "645--651",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults

T2 - Benefits, risks, or burden?

AU - Nachega, Jean B.

AU - Rosenkranz, Bernd

AU - Pham, Paul

PY - 2011

Y1 - 2011

N2 - The recent development of once-daily antiretroviral agents and fixed-dose combination formulations has been an important development in antiretroviral regimen simplification. Recent studies indicate that once-daily antiretroviral regimens improve adherence, especially in antiretroviral-naïve patients and in difficult-to-treat populations, such as the homeless or marginally housed. However, there are potential risks with the higher peak and lower trough plasma drug concentrations that may result from certain once-daily formulations. Due to the multifactorial and complex nature of adherence behavior, clinicians' efforts to improve patient adherence should not be limited to prescribing once-daily regimens, but should also consider social support, side effect management, and adherence support tools, such as pillbox organizers and other targeted interventions. Additional research will clarify the benefits of once-daily and fixed-dose combination regimens on clinical and virologic outcomes. Comprehensive cost-benefit analysis of regimen simplification could help facilitate evidence-based decisions regarding antiretroviral regimen choices.

AB - The recent development of once-daily antiretroviral agents and fixed-dose combination formulations has been an important development in antiretroviral regimen simplification. Recent studies indicate that once-daily antiretroviral regimens improve adherence, especially in antiretroviral-naïve patients and in difficult-to-treat populations, such as the homeless or marginally housed. However, there are potential risks with the higher peak and lower trough plasma drug concentrations that may result from certain once-daily formulations. Due to the multifactorial and complex nature of adherence behavior, clinicians' efforts to improve patient adherence should not be limited to prescribing once-daily regimens, but should also consider social support, side effect management, and adherence support tools, such as pillbox organizers and other targeted interventions. Additional research will clarify the benefits of once-daily and fixed-dose combination regimens on clinical and virologic outcomes. Comprehensive cost-benefit analysis of regimen simplification could help facilitate evidence-based decisions regarding antiretroviral regimen choices.

KW - Fixed-dose combination

KW - Health care costs

KW - Once-daily antiretroviral drugs

KW - Regimen adherence

KW - Regimen simplification

UR - http://www.scopus.com/inward/record.url?scp=84866492299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866492299&partnerID=8YFLogxK

U2 - 10.2147/PPA.S27558

DO - 10.2147/PPA.S27558

M3 - Article

VL - 5

SP - 645

EP - 651

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -